Please find attached Press Release on financial results for Q4 FY 26.

Revenue growth above 20%EBITDA margin compressionNet loss reportedExceptional itemResults View source PDF Explain this filing

GALAXYSURF · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.8%Reaction day

₹1840.00

prior close

₹1827.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.4%-0.4% vs market

Specialty Chemicals peers, median of 92sector-1.1%+0.2% vs sector

On the reaction day the stock moved 0.4 pts less than Nifty Microcap 250 and 0.2 pts more than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.3

10m

-0.1

15m

-0.0

30m

+0.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.8-0.4-0.4-1.1+0.2

Next day

-2.2-1.7-0.5-2.2+0.0

-1.4-1.3-0.2-1.8+0.3

-1.2-0.7-0.5-1.3+0.1

-1.1+0.4-1.5-0.8-0.2

-0.8+0.5-1.3-1.7+0.9

-0.9+2.8-3.7-0.4-0.5

15d

-5.9+1.2-7.1-2.3-3.6

-4.1+5.3-9.4+0.9-5.0

+6.9+9.9-3.0-0.1+7.0

+29.6+13.1+16.5+4.1+25.5

UpDownMarket · Nifty Microcap 250Sector · Specialty Chemicals peers, median of 92Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Galaxy Surfactants reported Q4FY26 revenue of Rs 1,315 crore, up 14.1% YoY, but EBITDA fell 9.5% to Rs 121.9 crore with margins compressing to 9.3% from 11.7% a year ago. PAT dropped 17.7% to Rs 62.4 crore, partly impacted by Rs 11.9 crore charge from new labour codes. For full year FY26, revenue grew 24% to Rs 5,270.4 crore, but EBITDA declined 2.5% and PAT fell 12.3%. India showed resilient high single-digit volume growth, while AMET region saw mid-teens decline due to logistics disruptions from the West Asia conflict. Specialty Care products posted strong growth, offsetting weakness in Performance Surfactants. Americas showed sequential improvement after tariff reversals.

Likely market impact

Revenue growth of 24% for FY26 is strong, but margin compression and PAT decline indicate profitability headwinds from geopolitical disruptions and input cost pressures. The stock may face near-term pressure unless margins recover.